Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush

This article was originally published in PharmAsia News

Executive Summary

More than 50 biotechs in China are now developing immuno-oncology assets centered mainly on the checkpoint inhibitor PD-1, meaning the emerging and promising treatment area is quickly becoming a crowded battlefield, insiders at a recent ChinaBio partnering event cautioned.


Related Content

Zai Lab Soars On Nasdaq Debut
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
China Surprises With First CRISPR Trial Despite Regulatory Lag, Concerns


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts